Nonalcoholic steatohepatitis (NASH) is a more aggressive form of liver disease. It is inflammatory in nature, is much quicker in disease progression than the standard type and may result in liver cirrhosis and failure. Both in clinical practice and in underwriting, NASH is under-recognized in its incidence. It actually affects up to five percent of the United States population and its prevalence is on the rise.
NASH affects between 2 and 5 percent of Americans and is not always a benign disease or an incidental finding. Along with hepatitis B and hepatitis C, it is attracting large amounts of research dollars in the study of its prevention and treatment.